Takeda Signs Up to $1.7B Deal to Use Iambic’s AI Technology for Drug Discovery

The Tokyo-based drugmaker will gain access to Iambic’s suite of AI-driven discovery technologies, including its generative modeling system NeuralPLexer, as it looks to advance small molecule programs across oncology, gastrointestinal and inflammation indications. The agreement includes upfront payments covering research costs and technology access, though the companies did not disclose specific figures. Milestone payments tied to development and commercialization achievements could push the total value of the collaboration past $1.7 billion, according to Fierce BioTech, citing a Feb. 9 press release.

The size of the potential payout places the arrangement among the largest artificial intelligence–focused drug discovery partnerships to date, per Fierce BioTech, underscoring the pharmaceutical industry’s increasing appetite for AI-enabled research platforms.

Iambic CEO Tom Miller sought to distinguish his company from what he characterized as hype surrounding artificial intelligence in biotech. “As you think about the AI space, work your way through landscape, and categorize Iambic as company, it is not about AI hype,” Miller told Fierce Biotech. “We are showing in patients that these drugs are better, creating validation.”

Under the terms of the deal, Takeda will deploy Iambic’s software tools and drug discovery capabilities to help identify and optimize new therapeutic candidates. NeuralPLexer, one of the centerpiece technologies included in the agreement, is designed to model protein–ligand interactions, a key step in predicting how potential drugs bind to their biological targets.

In a statement announcing the partnership, Miller said, “Our collaboration with Takeda is a powerful opportunity to apply our AI-driven discovery and development platform, and we are excited to partner with their team to quickly advance new and better drug candidates.” He added, “This collaboration further validates our industry-leading technology and highlights both the breadth of our discovery capabilities and the scale at which we can operate.”

We’d love to be your preferred source for news.

Please add us to your preferred sources list so our news, data and interviews show up in your feed. Thanks!

Add as Preferred Source

Read more: Senators Push Back as Trump Admin Greenlights Direct-to-Consumer Drug Sales 

According to Fierce BioTech, the arrangement stands out for Iambic because it encompasses both licensing of software and the deployment of its broader discovery infrastructure. The company’s platform is structured around what it describes as a rapid “design-make-test-analyze” cycle intended to compress development timelines and uncover novel chemical approaches to hard-to-drug targets.

“The Takeda deal is a combination of both tech deployment and involved drug discovery,” Miller said in the interview with Fierce BioTech. “It continues traction in the ways which we can monetize the platform.”

While Iambic has assembled a growing list of collaborators — including Revolution Medicines, Jazz Pharmaceuticals and Lundbeck, according to Fierce BioTech — Miller emphasized that partnership decisions are made selectively. He indicated that the company prioritizes agreements that strengthen its internal pipeline rather than simply expanding its roster of deals.

The AI drug discovery sector has expanded rapidly in recent years, but relatively few companies have advanced candidates into the clinic, and even fewer have generated differentiated clinical data, per Fierce BioTech. Iambic’s lead program, IAM1363, an oral oncology candidate, produced encouraging early-stage clinical results last fall ahead of a $100 million fundraising round completed in November.

Although Iambic’s platform is not limited to any single disease area — with internal and partnered programs spanning migraines, cancer, gastrointestinal and inflammatory disorders — the Takeda alliance marks another milestone for the company’s strategy of pairing AI-driven design with traditional drug development.

For Miller, the agreement signals a shift from promise to proof. “This deal is reinforcing our thesis that better tech leads to better meds,” he said. “It provides a validation and value assignment, showing patients that these drugs are better.”

Source: Fierce BioTech